

NICE technology appraisals for medicines

Formulary adherence checklist

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals	53
CCG commissioned	9
Non-CCG commissioned	28
Not applicable	17
CCG commissioned and approved	9 (100%)
Average days to compliance	32

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Acalabrutinib for treating chronic lymphocytic leukaemia [TA689]	Recommended	21/04/2021	TA	20/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Teduglutide for treating short bowel syndrome (terminated appraisal) [TA690]	Terminated appraisal	21/04/2021	TA					n/a	Link added to formulary
Avelumab for untreated metastatic Merkel cell carcinoma [TA691]	Recommended	21/04/2021	TA	20/07/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [TA692]	Not recommended	28/04/2021	TA					n/a	Link added to formulary Replaces TA519
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer [TA693]	Recommended	28/04/2021	TA	27/07/2021	Non-CCG			This technology is commissioned by NHS England (CDF). Providers are NHS hospital trusts.	Link added to formulary
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia [TA694]	Recommended	28/04/2021	TA	27/07/2021	CCG	26/05/2021	28	This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts and GPs.	Pan Mersey APC green statement
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma [TA695]	Recommended	28/04/2021	TA	27/07/2021	Non-CCG			This technology is commissioned by NHS England.	Link added to formulary
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [TA696]	Not recommended	12/05/2021	TA					n/a	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban [TA697]	Recommended	12/05/2021	TA	10/08/2021	CCG	26/05/2021	14	This technology is commissioned by integrated care systems (ICSs)/ clinical commissioning groups (CCGs). Providers are NHS hospital trusts	Pan Mersey APC red statement
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [TA698]	Recommended	19/05/2021	TA	17/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Ofatumumab for treating relapsing multiple sclerosis [TA699]	Recommended	19/05/2021	TA	17/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) [TA700]	Terminated appraisal	19/05/2021	TA					n/a	Link added to formulary
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) [TA701]	Terminated appraisal	19/05/2021	TA					n/a	Link added to formulary
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) [TA702]	Terminated appraisal	26/05/2021	TA					n/a	Link added to formulary
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) [TA703]	Terminated appraisal	26/05/2021	TA					n/a	Link added to formulary
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [TA704]	Recommended	26/05/2021	TA	24/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer [TA705]	Recommended	02/06/2021	TA	31/08/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Ozanimod for treating relapsing-remitting multiple sclerosis [TA706]	Not recommended	09/06/2021	TA					n/a	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer [TA707]	Recommended	15/06/2021	TA	13/09/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis [TA708]	Recommended	23/06/2021	TA	21/09/2021	CCG	28/07/2021	35	This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [TA709]	Recommended	23/06/2021	TA	21/09/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Ravulizumab for treating atypical haemolytic uraemic syndrome [TA710]	Recommended	23/06/2021	TA	21/09/2021	Non-CCG			This technology is commissioned by NHS England. Providers are tertiary care providers.	Link added to formulary
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [TA711]	Recommended	30/06/2021	TA	28/09/2021	CCG	28/07/2021	28	This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Enzalutamide for treating hormone-sensitive metastatic prostate cancer [TA712]	Recommended	07/07/2021	TA	05/10/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy [TA713]	Recommended	07/07/2021	TA	05/10/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) [TA714]	Terminated appraisal	14/07/2021	TA					n/a	Link added to formulary
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed [TA715]	Recommended	14/07/2021	TA	12/10/2021	CCG	28/07/2021	14	These technologies are commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [TA716]	Recommended	28/07/2021	TA	26/10/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS trust hospitals.	Link added to formulary
Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal) [TA717]	Terminated appraisal	21/07/2021	TA					n/a	Link added to formulary
Ixekizumab for treating axial spondyloarthritis [TA718]	Recommended	21/07/2021	TA	19/10/2021	CCG	22/09/2021	63	This technology is commissioned by integrated care systems / clinical commissioning groups. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Secukinumab for treating non-radiographic axial spondyloarthritis [TA719]	Recommended	21/07/2021	TA	19/10/2021	CCG	22/09/2021	63	This technology is commissioned by integrated care systems / clinical commissioning groups.	Pan Mersey APC red statement
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [TA720]	Recommended	18/08/2021	TA	16/11/2021	Non-CCG			This technology is commissioned by NHS England and Improvement. Providers are NHS hospital trusts.	Link added to formulary
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer [TA721]	Not recommended	18/08/2021	TA					n/a	Link added to formulary
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [TA722]	Recommended	25/08/2021	TA	23/11/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Bimekizumab for treating moderate to severe plaque psoriasis [TA723]	Recommended	01/09/2021	TA	30/11/2021	CCG	22/09/2021	21	This technology is commissioned by integrated care systems/clinical commissioning groups and strategic transformation partnerships. Providers are NHS hospital trusts.	Pan Mersey APC red statement
Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer [TA724]	Not recommended	08/09/2021	TA					n/a	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [TA725]	Recommended	15/09/2021	TA	14/12/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA726]	Terminated appraisal	22/09/2021	TA					n/a	Link added to formulary
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) [TA727]	Terminated appraisal	22/09/2021	TA					n/a	Link added to formulary
Midostaurin for treating advanced systemic mastocytosis [TA728]	Recommended	22/09/2021	TA	21/12/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS trust hospitals.	Link added to formulary
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria [TA729]	Recommended	29/09/2021	TA	28/12/2021	Non-CCG			This technology is commissioned by NHS England. Providers are NHS trust hospitals.	Link added to formulary
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal) [TA730]	Terminated appraisal	29/09/2021	TA					n/a	Link added to formulary
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) [TA731]	Terminated appraisal	29/09/2021	TA					n/a	Link added to formulary
Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal)	Terminated appraisal	06/10/2021	TA					n/a	Link added to formulary
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia	Recommended	06/10/2021	TA	04/01/2022	CCG	27/10/2021	21	The technology is commissioned by integrated care systems or clinical commissioning groups. Providers are primary care services.	Pan Mersey APC green statement
Secukinumab for treating moderate to severe plaque psoriasis in children and young people	Recommended	07/10/2021	TA	05/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Tofacitinib for treating juvenile idiopathic arthritis	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Berotralstat for preventing recurrent attacks of hereditary angioedema	Recommended	20/10/2021	TA	18/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable	Recommended	27/10/2021	TA	25/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer	Recommended	27/10/2021	TA	25/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer	Recommended	28/10/2021	TA	26/01/2022	Non-CCG			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	Link added to formulary